Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India

Abstract

IntroductionAs per the COVID-19 treatment guidelines of India, remdesivir and convalescent plasma therapy (CPT) are indicated in moderate and severe patients. In this study, we have evaluated the comparative safety and efficacy of remdesivir versus remdesivir CPT combination and effect of early versus late initiation of remdesivir. Materials and methodsA hospital-based observational study was conducted among hospitalized moderate and severe COVID-19 patients treated with either remdesivir and/or CPT as per national guidelines. Response to therapy was evaluated in terms of mortality, mechanical ventilation requirement, ICU requirement, and safety. Results and observationsA total of 95 moderate and severe COVID-19 patients on remdesivir (n=35) or remdesivir + CPT combination (n=60) were included. Both the remdesivir and remdesivir + CPT groups were comparable in terms of baseline characteristics, however, proportion of patients with baseline serum creatinine >1.5 was higher in the remdesivir group. No difference was seen between both the groups in terms of mortality, mechanical ventilation requirement, ICU requirement, and safety parameters in the overall moderate and severe COVID-19 populations and when each of these severity categories (moderate and severe) were analyzed separately. Early initiation (<9 days from symptom onset) of remdesivir was associated with better treatment outcome in terms of mortality and requirement of ICU. Post-therapy shortness of breath and LFTs (liver function tests) elevation was more in the late initiation of remdesivir group, which may be due to the lack of efficacy and subsequent disease progression or a direct effect of the drug. The beneficial effect of remdesivir was maintained even after adjustment for important prognostic factors and baseline imbalances (age, sex, disease severity, CPT use, and serum creatinine level). ConclusionsEarly initiation of remdesivir was associated with clinical benefit in terms of mortality and mechanical ventilation requirement. However, addition of convalescent plasma therapy as an additional therapeutic modality to remdesivir was not found to be beneficial.

Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients

“…No major untoward effects related to Remdesivir were observed in this study. This is in contradiction to the previous studies, which reported other side effects, such as diarrhea and rash [ 49 , 50 ]. Remdesivir elevated the ALT levels mildly in three patients (3.61%) after three doses, but remained static after five doses.…”

Histological Assessment of Remdesivir On kidney and Liver of Albino Rats in Different Doses And their Withdrawal

“…Liver and kidney toxicity may be due to the destruction of the lysosomal membrane caused by remdesivir leading to the liberation of their hydrolytic enzymes, which promote death and lysis of the cells (32). In the present study, distortion in the histological structure of the liver and kidneys could be due to the intermediate substances secreted by inflammatory cells, causing vasodilation and congestion of blood vessels (33).…”